

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Adverse Events Module

Results Database Train-the-Trainer Workshop
September 2015



<http://ClinicalTrials.gov>

FDAAA 801 - Adverse Events

“A table of anticipated and unanticipated serious adverse events grouped by organ system, with number and frequency of such event in each arm of the clinical trial.”

[Sec. 282(j)(3)(l)(iii)(I)]

FDAAA 801 – Adverse Events (cont.)

“A table of anticipated and unanticipated adverse events **that are not included in the [Serious Adverse Events] table**...that exceed a frequency of 5 percent within any arm of the clinical trial, grouped by organ system, with number and frequency of such event in each arm of the clinical trial.”

[Sec. 282(j)(3)(I)(iii)(II)]

FDAAA 801 = Section 801 of the Food and Drug Administration Amendments Act of 2007

3

Results: Adverse Events

Publication

Table 2. Adverse events in the safety population*

Adverse event	Placebo (n = 88)	Rituximab (n = 169)
Any treatment-emergent SAE	32 (36.4)	64 (37.9)
Any treatment-emergent SAE reported in ≥5% of patients		
Cardiac disorder	5 (5.7)	5 (3.0)
Infections and infestations	15 (17.0)	16 (9.5)
Gastrointestinal disorders	7 (8.0)	8 (4.7)
General disorder	5 (5.7)	7 (4.1)
Musculoskeletal and connective tissue disorders	5 (5.7)	9 (5.3)
Neutropenia	0 (0)	6 (3.6)
Any study drug-related treatment-emergent SAE	8 (9.1)	13 (7.7)
Any infusion-related AE	34 (38.6)	74 (43.8)
First infusion	26 (29.5)	46 (27.2)
Second infusion	14 (16.5)	29 (17.6)
Third infusion	7 (10.0)	23 (16.3)
Fourth infusion	4 (5.9)	25 (18.5)
Any infusion-related SAE	15 (17.0)	16 (9.5)
Any treatment-emergent infection-related SAE	15 (17.0)	16 (9.5)
Any treatment-emergent infection-related SAE reported in ≥2% of patients		
Lower respiratory tract and lungs	4 (4.5)	5 (3.0)
Bacterial	4 (4.5)	4 (2.4)
Abdominal and gastrointestinal	4 (4.5)	2 (1.2)
Sepsis, bacteremia, viremia, and fungemia NEC	3 (3.4)	2 (1.2)
Death	1 (1.1)	4 (2.4)

* Values are the number (%). SAE = serious adverse event; NEC = not elsewhere classified.

ClinicalTrials.gov

Serious Adverse Events

	Placebo + Prednisone	Rituximab + Prednisone
Total # participants affected/at risk	32/88 (36.36%)	68/169 (40.24%)
Blood and lymphatic disorders		
Neutropenia	0/88 (0.00%)	6/169 (3.55%)
Pancytopenia	1/88 (1.14%)	1/169 (0.59%)
Haemolytic Anaemia	0/88 (0.00%)	1/169 (0.59%)
Lymphopenia	0/88 (0.00%)	1/169 (0.59%)
Thrombocytopenia	0/88 (0.00%)	1/169 (0.59%)
Cardiac disorders		
Coronary artery disease

4

Serious Adverse Event Template

http://prsinfo.clinicaltrials.gov/results_table_layout/ResultSimpleForms.html

Time Frame for Adverse Event Reporting												
Adverse Event Reporting Additional Description												
Source Vocabulary Name for Table Default ①												
Assessment Type for Table Default ①		(Circle One) Systematic Non-Systematic										
* Arm/Group Title												
Arm/Group Description ②												
* Serious Adverse Events												
		* Number Participants Affected	* Number Participants at Risk	Number Events	* Number Participants Affected	* Number Participants at Risk	Number Events	* Number Participants Affected	* Number Participants at Risk	Number Events		
* Total Number for Serious Adverse Events												
* Adverse Event Term	* Organ System											
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	

* Required by ClinicalTrials.gov
[*] Conditionally required by ClinicalTrials.gov

5

Other Adverse Event Template

http://prsinfo.clinicaltrials.gov/results_table_layout/ResultSimpleForms.html

Time Frame for Adverse Event Reporting												
Adverse Event Reporting Additional Description												
Source Vocabulary Name for Table Default ①												
Assessment Type for Table Default ①		(Circle One) Systematic Non-Systematic										
* Arm/Group Title												
Arm/Group Description ②												
* Other (Not Including Serious) Adverse Events												
* Frequency Threshold (0–5%)	___%	* Number Participants Affected	* Number Participants at Risk	Number Events	* Number Participants Affected	* Number Participants at Risk	Number Events	* Number Participants Affected	* Number Participants at Risk	Number Events		
* Total Number for Other (Not Including Serious) Adverse Events												
* Adverse Event Term	* Organ System											
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	
	③	④[*]			④[*]			④[*]			④[*]	

* Required by ClinicalTrials.gov
[*] Conditionally required by ClinicalTrials.gov

6

Adverse Event Checklist

http://prsinfo.clinicaltrials.gov/results_table_layout/ResultSimpleForms.html

Adverse Event Data Preparation Checklist

Overview: Two tables reporting: (1) ALL anticipated and unanticipated **serious adverse events**; (2) anticipated and unanticipated **other adverse events**. Use this checklist with the [Serious Adverse Event Template](#), [Other \(Not Including Serious\) Adverse Event Template](#), and [Results Data Element Definitions](#).

General Adverse Event (AE) information to have available		Term
<input type="checkbox"/>	Time period over which AEs were assessed/collected <ul style="list-style-type: none"> Be specific. Indicate the length of time each participant was followed. (e.g., "up to 2 years" is specific; "until end of study" is not) 	¹ Time Frame for Adverse Event Reporting
<input type="checkbox"/>	If a standard dictionary or structured vocabulary was used to describe AEs, provide the name and version (e.g., MedDRA 10.0).	² Source Vocabulary Name for Table Default
<input type="checkbox"/>	Method for AE assessment: "Systematic" (e.g., solicited by a questionnaire) or "Non-systematic" (e.g., unsolicited)	³ Assessment Type for Table Default
<input type="checkbox"/>	Explanation of methods used for adverse event data collection or reporting Information about how you determined the number of participants assessed	⁴ Adverse Event Reporting Additional Description
<input type="checkbox"/>	Number of separate groups for which summary AE data will be provided Tip: Generally equal to the number of intervention strategies evaluated	Arms/Groups
<input type="checkbox"/>	For each group: <ul style="list-style-type: none"> Title—A descriptive label for the group (header for table column). Use informative labels (e.g., "Placebo"), not generic labels (e.g., "Group 1"). Description—A detailed explanation of the participants included in the group and the interventions received. This may include a description of how groups of participants were recombined for analysis purposes. 	⁵ Arm/Group Title ⁶ Arm/Group Description
Serious Adverse Event (SAE) information		Term
<input type="checkbox"/>	For each group, the total number of participants who: (1) reported at least one SAE; (2) were assessed for SAEs (i.e., could have reported an SAE)	Total for Serious AEs ⁷ Participants Affected ⁸ Participants at Risk
<input type="checkbox"/>	Name of each SAE and its Organ System (see categories in the Results Data Element Definitions)	⁹ Adverse Event Term ¹⁰ Organ System
<input type="checkbox"/>	Number of participants with the SAE in each group <ul style="list-style-type: none"> Optional—Number of occurrences of each event [Number of Events] 	¹¹ Number Participants Affected
Other (Not Including Serious) Adverse Event (OAE) information		Term
<input type="checkbox"/>	Frequency above which OAEs will be reported (0-5%). For example, if "5," report each OAE occurring in more than 5% of participants in any group	¹² Frequency Threshold
<input type="checkbox"/>	For each group, the total number of participants who: (1) reported any OAEs above frequency threshold; (2) were assessed for OAEs (i.e., could have reported an OAE)	Total for Other AEs ¹³ Participants Affected ¹⁴ Participants at Risk
<input type="checkbox"/>	Name of each OAE and its Organ System (see categories in the Results Data Element Definitions)	¹⁵ Adverse Event Term ¹⁶ Organ System
<input type="checkbox"/>	Number of participants with the OAE in each group <ul style="list-style-type: none"> Optional—Number of occurrences of each event [Number of Events] 	¹⁷ Number Participants Affected

7

¹Required
²Template Field

Adverse Event Module Key Points

- Summary data at the end of the study
 - Not "real time" adverse event reporting while the study is ongoing
- Serious Adverse Events and Other (not including serious) Adverse Events in separate tables
- Data reported in accordance with procedures for data collection in protocol
 - Use "Additional Description" to describe methods, as needed

8

Best Practices

- Specify the Time Frame for Adverse Event Reporting
- Use the Adverse Event Reporting Additional Description to provide information on the methods for adverse event data collection and on the analysis population (Number of Participants at Risk)

9

Other Data Entry Format: Upload Tab Delimited File

- Download a tab delimited file (with Arms/Groups)
- Use spreadsheet program (e.g., Excel) to enter adverse event information
- Upload tab delimited file(s) to populate adverse event table(s) in PRS

10

Adverse Events Tutorial

Results Section

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Results Section

[Record Summary](#) [Preview Results](#) [Download Results XML](#) [Delete Results](#) [Help](#)

[Open](#) **Participant Flow**
Pre-assignment Details
Trial Period: Overall Study Total Started: 200 [Protocol Enrollment: 200]

[Open](#) **Baseline Characteristics**
Overall Number of Baseline Participants: 200
Age, Continuous
Gender, Male/Female
Race/Ethnicity, Customized
Region of Enrollment
Quebec Task Force Classification of Spinal Disorders [Study-Specific Measure]
Body Mass Index [Study-Specific Measure]
Short Pain Scale (SPS-11) Score [Study-Specific Measure]
Duration of Condition A [Study-Specific Measure]
Height [Study-Specific Measure]
Weight [Study-Specific Measure]

[Open](#) **Outcome Measures**
Primary Outcome Measure(s)
1. Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24 [Time Frame: Week 24]
Secondary Outcome Measure(s)
2. Data Not Reported Number of Patients With a 50 Percent or Greater Reduction in Pain as Determined by SPS-11 at Week 12 [Time Frame: Week 12]
3. Data Not Reported Number of Patients With a 50 Percent or Greater Reduction in Pain as Determined by SPS-11 at Week 24 [Time Frame: Week 24]
4. Data Not Reported Patient's Overall Pain Relief (POPR) at Week 24 [Time Frame: Week 24]

[Edit](#) **Adverse Events**
Information is required

Select Adverse Event Arms/Groups

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Select Adverse Event Arms/Groups

Before entering Adverse Event data, use a Select button to define the Arms/Groups in your study. You can edit the information on the next screens.

[Help](#) [Definitions](#)

Copy from: Protocol Section <input type="button" value="Select"/>	Title	Remuverol	Arm/Group	Placebo
	Description	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks...	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol placebo tablet matching Remuverol orally twice daily for 24 weeks....

Copy from: Participant Flow <input type="button" value="Select"/>	Title	Remuverol	Arm/Group	Placebo
	Description	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.	Participants received Remuverol placebo tablet matching Remuverol orally twice daily for 24 weeks.

Create: New <input type="button" value="Select"/>	Define New Arms/Groups
---	------------------------

13

Edit Adverse Event Arms/Groups

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Edit Adverse Event Arms/Groups

Arms/Groups copied from: Participant Flow

 [Help](#) [Definitions](#)

* Arm/Group Title: Remuverol	Placebo
Arm/Group Description: Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks. <div style="text-align: right; font-size: x-small;">Characters remaining: 922</div>	Participants received Remuverol placebo tablet matching Remuverol orally twice daily for 24 weeks. <div style="text-align: right; font-size: x-small;">Characters remaining: 901</div>

14

Adverse Events Overview

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Adverse Events Overview

[Results Section](#) [Download/Upload](#) [Sort...](#) [Help](#) [Definitions](#) [Show All](#)

Edit	Time Frame	
	Additional Description	
	Source Vocabulary Name	[Not specified]
	Assessment Type	[Not specified]

Edit	Arm/Group Title	Remuverol	Placebo
	Arm/Group Description	Participants received Remuverol 15 ...	Participants received Remuverol pla...

▼ Serious Adverse Events
Information is required

		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
Edit	Total	--- /---	--- /---

[Add Serious Adverse Event](#)

▼ Other (Not Including Serious) Adverse Events
Information is required

Edit	Frequency Threshold for Reporting Other Adverse Events	%	
		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
Edit	Total	--- /---	--- /---

[Add Other \(Not Including Serious\) Adverse Event](#)

15

Edit Adverse Event Table Defaults

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Edit Adverse Event Table Defaults

[Help](#) [Definitions](#)

Time Frame for Adverse Event Reporting: Please provide description of period in which adverse event data were collected (e.g., 1 year, 6 months)
 Adverse events assessed for 24 weeks participants on intervention
 Characters remaining: 190

Additional Description: Characters remaining: 350

Source Vocabulary Name for Table Default: Please enter the name and version of the source vocabulary, if any, for adverse event terms. Source Vocabulary will be applied to all adverse event terms entered in the "Serious" and "Other" adverse event tables, unless otherwise specified.
 (e.g., SNOMED CT, MedDRA 10.0)
 MedDRA (12.0)

Assessment Type for Table Default: Assessment type will be applied to all adverse event terms entered in the "Serious" and "Other" adverse event tables, unless otherwise specified.
 If systematic, provide explanation of the method in Additional Description.
 Systematic Assessment

[Save](#) [Cancel](#)

16

Adverse Events Overview

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Adverse Events Overview

[Results Section](#) [Download/Upload](#) [Sort...](#) [Help](#) [Definitions](#) [Show All](#)

Edit	Time Frame	Adverse events assessed for 24 weeks participants on intervention	
	Additional Description		
	Source Vocabulary Name	MedDRA (12.0)	
	Assessment Type	Systematic Assessment	

Edit	Arm/Group Title	Remuverol	Placebo
	Arm/Group Description	Participants received Remuverol 15 ...	Participants received Remuverol pla...

▼ Serious Adverse Events
Information is required

Edit		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
	Total	--- /---	--- /---

[Add Serious Adverse Event](#)

▼ Other (Not Including Serious) Adverse Events
Information is required

Edit	Frequency Threshold for Reporting Other Adverse Events	Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
	%		
	Total	--- /---	--- /---

[Add Other \(Not Including Serious\) Adverse Event](#)

17

Edit Serious Adverse Event Total

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Edit Serious Adverse Event Total

[Help](#) [Definitions](#)

Serious Adverse Event(s)	Remuverol	Placebo
* Total Number Affected:	4 participants	0 participants
* Total Number At Risk:	101 participants	99 participants

Tip: The Total Number of Participants at Risk is typically equal to the Number of Participants who Started the first Period in the Participant Flow.
[Preview Participant Flow](#)

Save
Validate
Cancel

18

Adverse Events Overview

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Adverse Events Overview

[Results Section](#) [Download/Upload](#) [Sort...](#) [Help](#) [Definitions](#) [Show All](#)

Edit	Time Frame	Adverse events assessed for 24 weeks participants on intervention	
	Additional Description		
	Source Vocabulary Name	MedDRA (12.0)	
	Assessment Type	Systematic Assessment	

Edit	Arm/Group Title	Remuverol	Placebo
	Arm/Group Description	Participants received Remuverol 15 ...	Participants received Remuverol pla...

▼ Serious Adverse Events

		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
Edit	Total	4/101 (3.96%)	0/99 (0%)

[Add Serious Adverse Event](#)
● ERROR: At least one Serious Adverse Event must be entered when the Total Number Affected is greater than zero.

▼ Other (Not Including Serious) Adverse Events
Information is required

Edit	Frequency Threshold for Reporting Other Adverse Events	%	

		Remuverol Affected / at Risk (%)	Placebo Affected / at Risk (%)
Edit	Total	--- /---	--- /---

[Add Other \(Not Including Serious\) Adverse Event](#)

19

Add Serious Adverse Event

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Results: Add Serious Adverse Event

[Help](#) [Definitions](#)

* Adverse Event Term:

* Organ System:

Additional Description:

Source Vocabulary Name: (table default)

Assessment Type: (table default)

[Save](#)

20

Edit Serious Adverse Event Data

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Edit Serious Adverse Event Data

Table includes 1 Serious Adverse Event terms

[Help](#) [Definitions](#)

	Remuverol	Placebo
Total Number of Participants Affected/At Risk:	4 / 101	0 / 99
<div style="font-size: x-small; margin: 0;"> <input type="button" value="Edit"/> Anemia Blood and lymphati... MedDRA (12.0) Systematic Assessm... <input type="button" value="Delete"/> </div>	<div style="font-size: x-small; margin: 0;"> * Affected /At Risk: <input type="text" value="1"/> / 101 <input type="button" value="Edit"/> Number of Events: <input type="text"/> </div>	<div style="font-size: x-small; margin: 0;"> * Affected /At Risk: <input type="text" value="0"/> / 99 <input type="button" value="Edit"/> Number of Events: <input type="text"/> </div>

21

Edit Serious Adverse Event Data

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Edit Serious Adverse Event Data

Table includes 1 Serious Adverse Event terms

[Help](#) [Definitions](#)

	Remuverol	Placebo
Total Number of Participants Affected/At Risk:	4 / 101	0 / 99
<div style="font-size: x-small; margin: 0;"> <input type="button" value="Edit"/> Anemia Blood and lymphati... MedDRA (12.0) Systematic Assessm... <input type="button" value="Delete"/> </div>	<div style="font-size: x-small; margin: 0;"> * Affected /At Risk: <input type="text" value="1"/> / 101 <input type="button" value="Edit"/> Number of Events: <input type="text"/> </div>	<div style="font-size: x-small; margin: 0;"> * Affected /At Risk: <input type="text" value="0"/> / 99 <input type="button" value="Edit"/> Number of Events: <input type="text"/> </div>

* Adverse Event Term:

* Organ System:

Adverse Event Term Additional Description:

Characters remaining: 250

Source Vocabulary Name: (table default)

Assessment Type: (table default)

22

Edit Serious Adverse Event Data

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Edit Serious Adverse Event Data

Table includes 2 Serious Adverse Event terms

[Help](#) [Definitions](#)

	Remuverol	Placebo
Total Number of Participants	4 / 101	0 / 99
Affected / At Risk:		
Anemia	1 / 101 Edit	0 / 99 Edit
Number of Events:	<input type="text"/>	<input type="text"/>
Blood and lymphati... MedDRA (12.0) Systematic Assessm...		
Delete		
Idiopathic Thrombocytopenic Purpura	1 / 101 Edit	0 / 99 Edit
Number of Events:	<input type="text"/>	<input type="text"/>
Blood and lymphati... MedDRA (12.0) Systematic Assessm...		
Delete		

+ Add Serious Adverse Event x 2

[Save](#) [Validate](#) [Cancel](#)

23

Adverse Events Overview

ID: Parallel 2015 Parallel Study Design Example 2015 [NCT ID not yet assigned]

Adverse Events Overview

[Results Section](#) [Download/Upload](#) [Sort...](#) [Help](#) [Definitions](#) [Show All](#)

[Edit](#) Time Frame Adverse events assessed for 24 weeks participants on intervention

Additional Description

Source Vocabulary Name MedDRA (12.0)

Assessment Type Systematic Assessment

	Remuverol	Placebo
Arm/Group Title	Participants received Remuverol 15 ...	Participants received Remuverol pla...
Arm/Group Description		

Serious Adverse Events

	Remuverol	Placebo
	Affected / at Risk (%)	Affected / at Risk (%)
Total	4/101 (3.96%)	0/99 (0%)
Anemia TA	1/101 (0.99%)	0/99 (0%)
Idiopathic Thrombocytopenic Purpura TA	1/101 (0.99%)	0/99 (0%)
Viral Meningitis TA	1/101 (0.99%)	0/99 (0%)
Psoriasis TA	1/101 (0.99%)	0/99 (0%)

↑ Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA (12.0)

[Add Serious Adverse Event](#)

Other (Not Including Serious) Adverse Events
Information is required

	Remuverol	Placebo
	Affected / at Risk (%)	Affected / at Risk (%)
Total	--- / ---	--- / ---

[Add Other \(Not Including Serious\) Adverse Event](#)

24

Enter Adverse Events

- Example Study Designs
 - Crossover
 - Dose Escalation
 - Cluster Randomized
 - Factorial
 - Multiple Period